FDA OKs Abraxane With Gemcitabine for Pancreatic Cancer

New Drug Approvals

U.S. FOOD AND DRUG ADMINISTRATION APPROVES ABRAXANE® IN COMBINATION WITH GEMCITABINE AS FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC PANCREATIC CANCER

-Approval Based on MPACT Study of ABRAXANE in Combination with Gemcitabine Demonstrating a Clinically Meaningful Increase in Overall Survival-

-First New Treatment Approved for Metastatic Adenocarcinoma of the Pancreas in Nearly 8 Years-

SUMMIT, New Jersey– (September 6, 2013) – Celgene Corporation  (NASDAQ: CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s supplemental New Drug Application (sNDA) of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) as first–line treatment for patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.  Adenocarcinoma, a sub-type of exocrine tumors, accounts for about 95% of cancers of the pancreas.

read all at

http://www.pharmalive.com/fda-oks-abraxane-with-gemcitabine-for-pancreatic-cancer

Abraxane, a microtubule inhibitor, is an albumin-bound form of paclitaxel with a mean particle size of approximately 130 nanometers. Paclitaxel exists in the particles…

View original post 134 more words

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s